MCID: KDN017
MIFTS: 66

Kidney Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 40 14
Renal Cancer 12 72 51
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 69
Malignant Tumour of Kidney 12
Kidney Neoplasms 41
Renal Carcinoma 69
Kidney Neoplasm 69
Renal Neoplasm 28

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD10 32 C64
ICD9CM 34 189.0
MeSH 41 D007680

Summaries for Kidney Cancer

MedlinePlus : 40 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to hereditary leiomyomatosis and renal cell cancer and renal cell carcinoma, papillary, 1. An important gene associated with Kidney Cancer is VHL (Von Hippel-Lindau Tumor Suppressor), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 72 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Benign Neoplasm Kidney Carcinoma in Situ
Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 hereditary leiomyomatosis and renal cell cancer 32.8 FH HIF1A SDHB
2 renal cell carcinoma, papillary, 1 32.3 CA9 FH MET
3 von hippel-lindau syndrome 32.3 HIF1A SDHB TSC2 VEGFA VHL
4 angiomatosis 31.7 TSC2 VHL
5 fumarate hydratase deficiency 30.7 FH HIF1A VHL
6 hypoxia 30.3 CA9 HIF1A MTOR TP53 VEGFA VHL
7 bladder cancer 29.8 FGF2 IFNA2 IL2 RASSF1 TP53 VEGFA
8 leiomyosarcoma 29.7 FH TP53 WT1
9 hepatocellular carcinoma 29.5 FGF2 HIF1A KDR MET MTOR RASSF1
10 clear cell renal cell carcinoma 29.5 CA9 CD274 FLCN HIF1A KDR RASSF1
11 prostate cancer 29.4 FGF2 HIF1A KDR MET MTOR RASSF1
12 renal cell carcinoma, nonpapillary 29.2 ATM CA9 CD274 FGF2 FH FHIT
13 multilocular cystic renal neoplasm of low malignant potential 12.0
14 kidney cancer, childhood 11.9
15 chromophobe renal cell carcinoma 10.9
16 collecting duct carcinoma 10.9
17 congenital mesoblastic nephroma 10.8
18 childhood multilocular cystic kidney neoplasm 10.8
19 focal cortical dysplasia, type ii 10.7 MTOR TP53 TSC2
20 acute mountain sickness 10.7 HIF1A VEGFA VHL
21 epithelioid hemangioendothelioma 10.7 KDR VEGFA VHL
22 adult hepatocellular carcinoma 10.7 TP53 TSC2
23 kidney angiomyolipoma 10.7 FLCN MTOR TSC2
24 mucositis 10.7 IL2 MTOR VEGFA
25 cell type cancer 10.7 CD274 IL2 TP53 VEGFA
26 beckwith-wiedemann syndrome 10.7
27 wilms tumor 1 10.7
28 denys-drash syndrome 10.7
29 perlman syndrome 10.7
30 wilms tumor 5 10.7
31 kidney hemangiopericytoma 10.7
32 transitional cell carcinoma 10.7
33 kidney sarcoma 10.7
34 kidney clear cell sarcoma 10.7
35 hereditary paraganglioma-pheochromocytoma syndromes 10.7 FH SDHB VHL
36 recurrent respiratory papillomatosis 10.7 CD274 IFNA2 IL2
37 intravascular papillary endothelial hyperplasia 10.7 HIF1A VEGFA
38 kidney benign neoplasm 10.7 FLCN MTOR TSC2
39 familial renal oncocytoma 10.6 FH FLCN MET
40 angiosarcoma 10.6 KDR TP53 VEGFA
41 retinal hemangioblastoma 10.6 CA9 HIF1A VEGFA VHL
42 connective tissue cancer 10.6 FGF2 TP53 VEGFA
43 pericardial effusion 10.6 FGF2 HIF1A VEGFA
44 exudative vitreoretinopathy 1 10.6 HIF1A KDR VEGFA
45 radiation proctitis 10.6 FGF2 KDR VEGFA
46 nodular prostate 10.6 CA9 HIF1A KDR
47 adenosquamous pancreas carcinoma 10.6 HIF1A IFNA2 MET
48 lymphangioma 10.6 IFNA2 KDR VEGFA
49 angiomatous meningioma 10.6 FGF2 KDR VEGFA
50 endometrial adenocarcinoma 10.6 FGF2 TP53 VEGFA

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

GenomeRNAi Phenotypes related to Kidney Cancer according to GeneCards Suite gene sharing:

25 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.01 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.01 CD274
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.01 ATM MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.01 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.01 MTOR ATM
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.01 ATM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.01 CD274
8 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.01 CD274
9 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.01 WT1 ATM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.01 KDR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.01 ATM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.01 ATM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.01 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.01 ATM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.01 MTOR ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.01 MET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.01 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.01 MET
19 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.01 MET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.01 ATM WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.01 ATM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.01 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.01 CD274
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.01 CD274 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.01 CD274 KDR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.01 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.01 MET
28 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.01 ATM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.01 MTOR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.01 WT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.01 WT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.01 MET
33 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.01 MTOR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.01 ATM
35 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.01 MET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.01 ATM
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.01 WT1 CD274 KDR MET ATM MTOR
38 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 WT1 VHL

MGI Mouse Phenotypes related to Kidney Cancer:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 MTOR TP53 RASSF1 TSC2 VHL VEGFA
2 cardiovascular system MP:0005385 10.46 MTOR TP53 RASSF1 SDHB VHL VEGFA
3 homeostasis/metabolism MP:0005376 10.46 TP53 RASSF1 SDHB MTOR VHL VEGFA
4 hematopoietic system MP:0005397 10.43 MTOR TP53 SDHB VHL VEGFA TSC2
5 mortality/aging MP:0010768 10.41 TP53 RASSF1 SDHB MTOR VHL VEGFA
6 immune system MP:0005387 10.37 MTOR TP53 MET RASSF1 VHL VEGFA
7 endocrine/exocrine gland MP:0005379 10.36 SDHB MTOR TP53 RASSF1 TSC2 VHL
8 behavior/neurological MP:0005386 10.33 MTOR MET TSC2 TP53 VEGFA CD274
9 growth/size/body region MP:0005378 10.31 MTOR MET TSC2 TP53 VEGFA WT1
10 embryo MP:0005380 10.3 MTOR TP53 MET TSC2 VHL VEGFA
11 digestive/alimentary MP:0005381 10.22 MET RASSF1 VHL TP53 VEGFA FHIT
12 neoplasm MP:0002006 10.21 TP53 RASSF1 SDHB VHL VEGFA TSC2
13 liver/biliary system MP:0005370 10.16 TP53 MET RASSF1 TSC2 VHL VEGFA
14 integument MP:0010771 10.13 TSC2 TP53 VEGFA VHL FHIT CD274
15 muscle MP:0005369 10.06 MTOR MET TP53 VEGFA WT1 VHL
16 normal MP:0002873 10 SDHB MTOR MET RASSF1 TSC2 VHL
17 no phenotypic analysis MP:0003012 9.97 SDHB MTOR MET TP53 VEGFA WT1
18 renal/urinary system MP:0005367 9.9 MTOR TP53 SDHB TSC2 VHL VEGFA
19 respiratory system MP:0005388 9.56 MTOR MET TP53 VEGFA WT1 HIF1A
20 vision/eye MP:0005391 9.23 MET VEGFA TP53 VHL FGF2 HIF1A

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009
2
Avastin 17 45 BEVACIZUMAB Genentech July 2009
3
Inlyta 17 45 AXITINIB Pfizer January 2012
4
Nexavar 17 45 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Proleukin 17 45 ALDESLEUKIN Chiron January 1998
6
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
7
Torisel 17 45 TEMSIROLIMUS Wyeth May 2007
8
Votrient 17 45 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 552)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
2
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
6 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 329-65-7
7
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 110942-02-4, 85898-30-2
8
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
11
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 38396-39-3, 2180-92-9 2474
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
13
Zoledronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 118072-93-8 68740
14
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
15
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
16
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
17
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
18
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
19
Nicotine Approved Phase 4 54-11-5 89594 942
20
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
22
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
23
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
24
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-67-6 938
27
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 98-92-0 936
28
Caffeine Approved, Nutraceutical Phase 4,Phase 1 58-08-2 2519
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
33 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 interferons Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1721)

# Name Status NCT ID Phase Drugs
1 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
2 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
3 Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
6 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma Completed NCT00460798 Phase 4
7 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Completed NCT01339962 Phase 4
8 Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
9 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
10 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
11 Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
12 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Completed NCT01266837 Phase 4 Everolimus
13 Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
14 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
15 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4 Doxycycline;Placebo
16 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
17 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
19 Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma Recruiting NCT02399124 Phase 4
20 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. Recruiting NCT01206764 Phase 4 RAD001
21 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
22 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
23 Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy Recruiting NCT03323021 Phase 4
24 QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
25 Collaborative Wilms Tumour Africa Project Recruiting NCT01991652 Phase 4
26 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4 Nivolumab
27 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
28 Study of Nivolumab for Advanced Cancers in India Not yet recruiting NCT03444766 Phase 4 Nivolumab
29 Efficacy of IV Acetaminophen Versus Oral Acetaminophen Not yet recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
30 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
31 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
32 Cost Effectiveness Of Sunitinib In Central America And Caribbean Terminated NCT01033981 Phase 4 Sunitinib
33 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
34 Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
35 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4 Sunitinib malate
36 Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer Withdrawn NCT01353794 Phase 4 Sorafenib (Nexavar, BAY43-9006)
37 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4 Temsirolimus
38 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
39 Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
40 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
41 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
42 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
43 Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Completed NCT00416429 Phase 3 medroxyprogesterone
44 Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer Completed NCT00416871 Phase 3
45 AE-941 in Treating Patients With Metastatic Kidney Cancer Completed NCT00005995 Phase 3 shark cartilage extract AE-941
46 Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
47 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00018941 Phase 3
48 Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer Completed NCT00002473 Phase 3
49 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00005966 Phase 3 thalidomide
50 Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer Completed NCT00053807 Phase 3 fluorouracil

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Neoplasm 28

Anatomical Context for Kidney Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

18
The Kidney

MalaCards organs/tissues related to Kidney Cancer:

38
Kidney, Lung, Bone, Endothelial, Brain, Breast, Testes

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 716)
# Title Authors Year
1
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29358781 )
2018
2
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. ( 29368112 )
2018
3
Kidney cancer in 2017: Challenging and refining treatment paradigms. ( 29335524 )
2018
4
PTEN in kidney cancer: A review and meta-analysis. ( 29408173 )
2018
5
The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. ( 29381020 )
2018
6
Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer. ( 29424894 )
2018
7
Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. ( 29449090 )
2018
8
Kidney cancer: First-in-class HIF2I+ antagonist safe and effective. ( 29335652 )
2018
9
Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation. ( 29325224 )
2018
10
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. ( 29355171 )
2018
11
NICE recommends kidney cancer drug "likely to be less effective" than current treatments after price deal. ( 29449220 )
2018
12
Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. ( 29331568 )
2018
13
Rapid intra-operative diagnosis of kidney cancer by ATR-IR spectroscopy of tissue smears. ( 29316381 )
2018
14
Kidney cancer: PDL1 as a biomarker in high-risk RCC. ( 29434371 )
2018
15
HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. ( 29384723 )
2018
16
Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. ( 28798821 )
2017
17
Online tools for patient counseling in bladder and kidney cancer-ready for prime time? ( 29354499 )
2017
18
Second Primary Cancer Risk Among Kidney Cancer Patients in Korea: A Population-Based Cohort Study. ( 28421722 )
2017
19
Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012. ( 28781525 )
2017
20
SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. ( 28868352 )
2017
21
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer. ( 28827316 )
2017
22
Optional caval filter in kidney cancer patients with tumor thrombus level I and II. ( 28752725 )
2017
23
Basic/Translational Science Survey Section: Kidney Cancer. ( 28340689 )
2017
24
Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. ( 28423633 )
2017
25
A step towards predicting checkpoint inhibitor response in kidney cancer. ( 28759367 )
2017
26
Incorporating New Systemic Therapies in Kidney Cancer Treatment. ( 28515249 )
2017
27
Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study. ( 28314541 )
2017
28
Highlights in kidney cancer from the 2017 American Society of Clinical Oncology Annual Meeting. ( 28949939 )
2017
29
Setting Research Priorities for Kidney Cancer. ( 28495043 )
2017
30
Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. ( 27992843 )
2017
31
Synergistic Activity for Natural and Synthetic Inhibitors of Angiogenesis Induced by Murine Sarcoma L-1 and Human Kidney Cancer Cells. ( 28456932 )
2017
32
Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis. ( 28847686 )
2017
33
Hereditary Kidney Cancer Syndromes and Surgical Management of the Small RenalA Mass. ( 28411908 )
2017
34
Kidney cancer: Deciphering sarcomatoid RCC. ( 28762391 )
2017
35
Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment. ( 28459940 )
2017
36
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. ( 29382441 )
2017
37
A comprehensive analysis of cancer-driving mutations and genes in kidney cancer. ( 28454375 )
2017
38
Kidney cancer: Tracking and therapy selection using ctDNA. ( 28467397 )
2017
39
Kidney cancer: Path to progression: intracrine signalling in RCC. ( 28322261 )
2017
40
Medication use and kidney cancer risk: AA population-based study. ( 28750272 )
2017
41
Kidney cancer: Targeting Wilms tumour. ( 28890538 )
2017
42
Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study. ( 28063109 )
2017
43
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. ( 28061437 )
2017
44
Kidney cancer: Targeting metabolism in RCC. ( 28420887 )
2017
45
Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy. ( 27888385 )
2017
46
When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging: Indications for Preoperative Bone Scintigraphy. ( 28890151 )
2017
47
Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors. ( 28408240 )
2017
48
Potential Pathogenesis and Biomarkers of Kidney Cancer-Related Stroke. ( 28505148 )
2017
49
Accuracy of kidney cancer diagnosis and histological subtype within Canadian cancer registry data. ( 29382453 )
2017
50
Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. ( 28829506 )
2017

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6 (show all 39)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
5 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
6 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
10 MET NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 GRCh37 Chromosome 7, 116423414: 116423414
11 MET NM_001127500.2(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913243 GRCh37 Chromosome 7, 116417464: 116417464
12 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
13 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
14 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
15 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
16 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
17 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
18 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
19 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
20 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
21 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
22 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
23 VHL NM_000551.3(VHL): c.548C> A (p.Ser183Ter) single nucleotide variant Pathogenic rs5030823 GRCh37 Chromosome 3, 10191555: 10191555
24 VHL NM_000551.3(VHL): c.481C> T (p.Arg161Ter) single nucleotide variant Pathogenic/Likely pathogenic rs5030818 GRCh37 Chromosome 3, 10191488: 10191488
25 VHL NM_000551.3(VHL): c.499C> T (p.Arg167Trp) single nucleotide variant Pathogenic/Likely pathogenic rs5030820 GRCh37 Chromosome 3, 10191506: 10191506
26 ATM ATM, IVS61DS, 2-BP INS, +2TA insertion Pathogenic
27 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
28 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
29 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
30 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
31 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
32 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
33 MTOR NM_004958.3(MTOR): c.4447T> C (p.Cys1483Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519914 GRCh38 Chromosome 1, 11157174: 11157174
34 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
36 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
37 MTOR NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh37 Chromosome 1, 11184573: 11184573
38 MTOR NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 GRCh37 Chromosome 1, 11217299: 11217299
39 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905

Cosmic variations for Kidney Cancer:

9 (show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 15
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 15
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 15
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 15
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 15
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 15
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 15
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 15
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 15
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 15
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 15
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 15
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 15
14 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 13
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 13
16 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 13
17 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 13
18 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 13
19 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 13
20 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 13
21 COSM52899 PBRM1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3805A>T p.K1269* 13

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 ATM FGF2 HIF1A IL2 KDR MET
2
Show member pathways
13.55 FGF2 IFNA2 IL2 KDR MET MTOR
3
Show member pathways
13.37 FGF2 HIF1A IFNA2 IL2 MET TP53
4
Show member pathways
13.12 ATM CA9 HIF1A MTOR TP53 TSC2
5
Show member pathways
13.06 FGF2 IL2 KDR MET MTOR TP53
6
Show member pathways
13.04 FGF2 HIF1A IL2 KDR MET MTOR
7
Show member pathways
12.84 ATM FGF2 FHIT KDR MET MTOR
8 12.76 FGF2 KDR MET TP53 VEGFA
9
Show member pathways
12.73 FGF2 KDR MET RASSF1 VEGFA
10
Show member pathways
12.72 FGF2 MET MTOR TP53 TSC2
11
Show member pathways
12.68 ATM FGF2 IFNA2 IL2 KDR MET
12
Show member pathways
12.52 FGF2 HIF1A IFNA2 MTOR TP53 VEGFA
13 12.45 ATM MET MTOR RASSF1 TP53 VEGFA
14
Show member pathways
12.4 FLCN KDR MET MTOR TP53 TSC2
15
Show member pathways
12.39 FGF2 KDR MET VEGFA
16
Show member pathways
12.39 MET MTOR TP53 TSC2
17
Show member pathways
12.3 ATM IL2 KDR MET MTOR TP53
18
Show member pathways
12.26 HIF1A MTOR TP53 VEGFA
19 12.25 ATM MET TP53 WT1
20 12.25 CA9 FLCN HIF1A MTOR TSC2
21
Show member pathways
12.22 KDR MET MTOR TP53 TSC2
22 12.17 ATM MTOR TP53 TSC2
23 12.17 FGF2 HIF1A KDR MET MTOR TP53
24 12.1 ATM MTOR TP53 TSC2 VEGFA
25 12.09 FGF2 FH HIF1A IFNA2 IL2 MET
26 12.06 ATM KDR TP53 VEGFA
27 12.06 ATM MTOR TP53 TSC2
28
Show member pathways
12.01 FH FLCN HIF1A MET MTOR TP53
29 11.99 HIF1A MTOR TP53 TSC2
30 11.98 FGF2 HIF1A TP53 VEGFA
31 11.95 FGF2 KDR MET VEGFA WT1
32 11.91 HIF1A MTOR VEGFA VHL
33
Show member pathways
11.86 HIF1A KDR VEGFA VHL
34 11.84 CA9 FGF2 HIF1A KDR
35 11.82 MTOR TP53 TSC2
36 11.74 RASSF1 TP53 VEGFA
37
Show member pathways
11.74 ATM MTOR TP53
38 11.67 CA9 HIF1A VEGFA
39 11.67 ATM IL2 MTOR WT1
40 11.65 HIF1A MET MTOR TP53
41 11.63 ATM RASSF1 TP53
42 11.56 HIF1A TP53 VEGFA
43 11.54 FGF2 KDR VEGFA
44 11.51 HIF1A TP53 VEGFA VHL
45 11.5 ATM MTOR TSC2
46 11.5 FGF2 KDR VEGFA
47 11.45 MTOR TP53 TSC2
48
Show member pathways
11.45 KDR MET VEGFA
49 11.45 FGF2 KDR VEGFA
50 11.38 HIF1A TP53 VEGFA

GO Terms for Kidney Cancer

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.91 FGF2 HIF1A KDR VEGFA
2 negative regulation of apoptotic process GO:0043066 9.91 HIF1A IL2 KDR TP53 VEGFA VHL
3 positive regulation of angiogenesis GO:0045766 9.84 FGF2 HIF1A KDR VEGFA
4 cellular response to hypoxia GO:0071456 9.81 HIF1A MTOR TP53 VEGFA
5 positive regulation of protein phosphorylation GO:0001934 9.8 FLCN IL2 KDR MTOR VEGFA
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.79 MTOR TP53 VEGFA
7 Ras protein signal transduction GO:0007265 9.77 FGF2 RASSF1 TP53
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNA2 IL2 VEGFA
9 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.76 CA9 HIF1A VEGFA VHL
10 vasculogenesis GO:0001570 9.75 KDR VEGFA WT1
11 cell cycle arrest GO:0007050 9.72 ATM MTOR RASSF1 TP53 TSC2
12 negative regulation of TOR signaling GO:0032007 9.7 FLCN HIF1A TSC2
13 positive regulation of macroautophagy GO:0016239 9.67 HIF1A KDR TSC2
14 determination of adult lifespan GO:0008340 9.63 ATM TP53
15 growth GO:0040007 9.63 MTOR VEGFA
16 replicative senescence GO:0090399 9.62 ATM TP53
17 positive regulation of positive chemotaxis GO:0050927 9.61 KDR VEGFA
18 cell migration involved in sprouting angiogenesis GO:0002042 9.61 FGF2 KDR VEGFA
19 anoikis GO:0043276 9.6 MTOR TSC2
20 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.57 KDR VEGFA
21 positive chemotaxis GO:0050918 9.56 FGF2 MET TSC2 VEGFA
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.55 HIF1A VEGFA
23 positive regulation of blood vessel endothelial cell migration GO:0043536 9.46 FGF2 HIF1A KDR VEGFA
24 negative regulation of gene expression GO:0010629 9.43 FLCN HIF1A IFNA2 KDR VEGFA VHL
25 positive regulation of endothelial cell proliferation GO:0001938 9.02 FGF2 HIF1A KDR MTOR VEGFA
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 FGF2 FLCN HIF1A IL2 MET TP53
27 positive regulation of transcription, DNA-templated GO:0045893 10.03 FGF2 HIF1A IFNA2 TP53 VHL WT1

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 ATM CA9 CD274 FGF2 FH FHIT
2 cytokine activity GO:0005125 9.26 FGF2 IFNA2 IL2 VEGFA

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....